



GLOBAL EXPERT SUMMIT ON HYPOPARATHYROIDISM

ASSESSING AND MANAGING A COMPLEX DISEASE

**Evolving goals and guidelines for the treatment of
hypoparathyroidism**

**Prof. Aliya Khan
Prof. John Bilezikian
Prof. Michal Kršek
Prof. Polyzois Makras**

20th–21st Nov, 2020

Code: VV-MEDMAT-2432 – Date of preparation: August 2020

This meeting is initiated, organized and funded by Takeda. This event is for healthcare professionals only.

Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC).

Copyright © 2020 Takeda Pharmaceutical Company Limited. All rights reserved. Takeda and the Takeda Logo are trademarks of Takeda Pharmaceutical Company Limited.

Transcript

Hello from Canada! My name is **Aliya Khan** and I'm an endocrinologist in Hamilton, Ontario.

Good day also from Greece! My name is **Polyzois Makras** and I'm endocrinologist and diabetologist in Athens.

And a warm welcome also from Czech Republic, my name is **Michal Kršek** and I'm diabetologist and endocrinologist in Prague.

And finally a very good day from the USA! My name is **John Bilezikian** and I'm endocrinologist at the Columbia University in New York!

Notes/Infographic or image on video

**Aliya Khan**

Professor of Clinical Medicine, Divisions of Endocrinology and Metabolism and Geriatrics at McMaster University, Director of the Calcium Disorders Clinic at McMaster University Medical Center
Hamilton, Ontario, Canada

**Polyzois Makras**

Deputy Director of Department of Endocrinology & Diabetes, Head of Department of Medical Research, Hellenic Air Force & VA General Hospital
Athens, Greece

**Michal Kršek**

Head of Clinic for Endocrinology and Metabolism, General University Hospital
Professor and Head of the Department of Internal Medicine, Charles University
Prague, Czech Republic

**John Bilezikian**

Professor of Medicine and Professor of Pharmacology at the College of Physicians & Surgeons
Chief of the Division of Endocrinology and Director of the Metabolic Bone Diseases Program
Columbia University Medical Center
New York, USA

Transcript

This session will focus on evolving treatment goals and guidelines for hypoparathyroidism.


I am currently leading an initiative aimed at developing new international guidelines for the diagnosis and management of hypoparathyroidism.

I will begin with a presentation on hormonal therapy for the treatment of hypoparathyroidism and on aligning recommendations for patient selection and use with clinical evidence.

During this presentation, I will focus on potential differences in outcomes that might be achieved with hormonal therapy vs standard management with a combination of calcium and vitamin D supplementation.

It has been noted that hormonal treatment has opened a “new era” for the management of hypoparathyroidism and I will summarize what we now know and still need to learn about this intervention.

Notes/Infographic or image on video



Human Parathyroid Hormone

Created by INNOTIO GmbH for Takeda
Date of preparation: August 2020

Transcript

(For **Prof Makras**):

As we gain more information about new therapies, there is a need to revisit and potentially revise our treatment guidelines.

Notes/Infographic or image on video



Examples for the many guidelines for treatment of hypoparathyroidism will appear in animated way on the side of the video



Images: Makras P, et al. *Hormones (Athens)*. Published online ahead of print, 2020 Apr 15.
 Castro A, et al. *Acta Otorrinolaringol Esp*. 2019;70(5):301-305.
 Khan AA, et al. *Eur J Endocrinol*. 2018;180(3):P1-P22.
 Orloff LA, et al. *Thyroid*. 2018;28(7):830-841.
 Maeda SS, et al. *Arch Endocrinol Metab*. 2018;62(1):106-124.
 Brandi ML, et al. *J Clin Endocrinol Metab*. 2016;101(6):2273-2283.
 Bollerslev J, et al. *Eur J Endocrinol*. 2015;173(2):G1-G20.

Transcript

(For Prof Kršek):

At present, there are multiple national and international guidelines for the diagnosis and treatment of hypoparathyroidism and harmonization of these recommendations would greatly benefit the clinical community.

Notes/Infographic or image on video



Examples for the many guidelines for treatment of hypoparathyroidism will appear in animated way on the side of the video




Images: Makras P, et al. *Hormones (Athens)*. Published online ahead of print, 2020 Apr 15.
Castro A, et al. *Acta Otorrinolaringol Esp*. 2019;70(5):301-305.
Khan AA, et al. *Eur J Endocrinol*. 2018;180(3):P1-P22.
Orloff LA, et al. *Thyroid*. 2018;28(7):830-841.
Maeda SS, et al. *Arch Endocrinol Metab*. 2018;62(1):106-124.
Brandi ML, et al. *J Clin Endocrinol Metab*. 2016;101(6):2273-2283.
Bollerslev J, et al. *Eur J Endocrinol*. 2015;173(2):G1-G20.

Transcript

(For **Prof Bilezikian**):

Together with many other experts, we will engage in a live, interactive panel discussion that will consider how to create a global guideline for the management of hypoparathyroidism and the strengths and limitations of the evidence available to support new recommendations.

Notes/Infographic or image on video



TEASER

4

Evolving goals and guidelines for the treatment of hypoparathyroidism



Transcript

For Prof Khan:

We are very much looking forward to a very dynamic session!

Thus, Save-the-Date and join us on November 21st!

Notes/Infographic or image on video



TEASER 4



GLOBAL EXPERT SUMMIT ON HYPOPARATHYROIDISM

ASSESSING AND MANAGING A COMPLEX DISEASE

Evolving goals and guidelines for the treatment of hypoparathyroidism



Save the date!

Code: VV-MEDMAT-2432 – Date of preparation: August 2020
This meeting is initiated, organized and funded by Takeda. This event is for healthcare professionals only.
Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC).
Copyright © 2020 Takeda Pharmaceutical Company Limited. All rights reserved.
Takeda and the Takeda Logo are trademarks of Takeda Pharmaceutical Company Limited.

TEASER

4



GLOBAL EXPERT SUMMIT ON HYPOPARATHYROIDISM

ASSESSING AND MANAGING A COMPLEX DISEASE

**Evolving goals and guidelines for the treatment
of hypoparathyroidism**

20, 21
Nov

Save the date!

Code: VV-MEDMAT-2432 – Date of preparation: August 2020

This meeting is initiated, organized and funded by Takeda. This event is for healthcare professionals only.

Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC).

Copyright © 2020 Takeda Pharmaceutical Company Limited. All rights reserved. Takeda and the Takeda Logo are trademarks of Takeda Pharmaceutical Company Limited.